Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -10.92 % |
3 Month Return | -9.08 % |
1 Year Return | + 75.36 % |
Market Stats | |
Previous Close | ₹2,356.45 |
Open | ₹2,414.00 |
Volume | 2,450.00 |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹1,388.42Cr |
P/E Ratio | 0 |
PEG Ratio | 0 |
Market Cap | ₹1,388.42 Cr |
P/B Ratio | 12.38 |
EPS | 0 |
Dividend Yield | 0.06 |
Sector | Pharmaceuticals |
ROE | 33.24 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
NA | ₹1,388.42 Cr | 84.92% | 0.51 | ₹25 Cr | ₹212 Cr | |
NA | ₹64.17 Cr | 258.28% | 0.50 | NA | NA | |
NA | ₹123.98 Cr | 53.7% | 0.69 | NA | NA | |
NA | ₹94.27 Cr | 188.71% | 0.51 | NA | NA | |
NA | ₹1,084.89 Cr | 1.66% | 0.79 | NA | NA |
Organisation | Remus Pharmaceuticals Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Remus Pharmaceuticals Ltd
Remus Pharmaceuticals Ltd saw a spike in trading volumes on Friday, with rumors of AK-47 of small and micro caps investing in the stock. The stock has tripled over the last year due to improved operating performance and low floating stock.
Remus Pharmaceuticals ROCE Falls Despite Revenue Increase - 27 Jun, 2024
Despite an increase in revenue and capital employed, Remus Pharmaceuticals' Return on Capital Employed (ROCE) has fallen from 39% to 25% in the last four years. The company's high current liabilities to total assets ratio of 58% introduces some risk, but reinvestment for growth could lead to long-term benefits for shareholders. The stock has returned 123% to shareholders in the last year.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
In the last 7 days, REMUS stock has moved up by 2.4%
Promoter Holding Up
Promoters have increased holdings from 70.60% to 70.66% in Jun 2024 quarter
Retail Holding Up
Retail Investor have increased holdings from 25.49% to 25.61% in Jun 2024 quarter
FII Holding Down
Foreign Institutions have decreased holdings from 3.25% to 3.00% in Jun 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 70.66% | 0.08 | |
Foreign Institutions | 3% | ||
Mutual Funds | 0% | 0.00 | |
Retail Investors | 25.61% | 0.50 | |
Others | 0.73% | 9.18 |
Bearish
Neutral
Bullish
Remus Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Remus Pharmaceuticals Ltd (REMUS) share price today is ₹2340.1
Remus Pharmaceuticals Ltd is listed on NSE
Remus Pharmaceuticals Ltd is not listed on BSE
Today’s traded volume of Remus Pharmaceuticals Ltd(REMUS) is 2,450.00.
Today’s market capitalisation of Remus Pharmaceuticals Ltd(REMUS) is ₹1388.42Cr.
Remus Pharmaceuticals Ltd(REMUS | Price |
---|---|
52 Week High | ₹2834.75 |
52 Week Low | ₹427.81 |
Remus Pharmaceuticals Ltd(REMUS) share price is ₹2340.1. It is down -17.45% from its 52 Week High price of ₹2834.75
Remus Pharmaceuticals Ltd(REMUS) share price is ₹2340.1. It is up 447.00% from its 52 Week Low price of ₹427.81
Remus Pharmaceuticals Ltd(REMUS | Returns |
---|---|
1 Day Returns | -16.35% |
1 Month Returns | -10.92% |
3 Month Returns | -9.08% |
1 Year Returns | 75.36% |